Brian C. Thomas
Equibles does not estimate personal net worth.
About Brian C. Thomas
Brian C. Thomas was last confirmed as CEO at Metagenomi Therapeutics, Inc. (MGX) in a filing dated April 28, 2025. Earlier roles on record: Board Member at Metagenomi Therapeutics, Inc. (MGX) until June 9, 2026. Metagenomi Therapeutics, Inc. reported in an 8-K filed June 10, 2026 that Brian C. Thomas resigned as member of the Board, effective June 9, 2026. The proxy statement of Metagenomi Therapeutics, Inc. reports total compensation of $1,396,061 for Brian C. Thomas in fiscal 2025, including a base salary of $563,014. Disclosed compensation is on record for 3 fiscal years.
“On June 9, 2026, Brian C. Thomas, Ph.D. informed the board of directors (the "Board") of Metagenomi Therapeutics, Inc. (the "Company") of his resignation from his position as a member of the Board, effective as of June 9, 2026.”
Affiliation history
-
Start not stated–2025-04-28
Last confirmed by a filing; no departure on record
-
Start not stated–2026-06-09
Company network
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Metagenomi Therapeutics, Inc. (MGX) | Former Chief Executive Officer | $563,014 | $1,396,061 |
| 2024 | Metagenomi Therapeutics, Inc. (MGX) | Chief Executive Officer | $628,333 | $6,061,284 |
| 2023 | Metagenomi Therapeutics, Inc. (MGX) | Chief Executive Officer | $516,667 | $7,825,855 |